Melanotan I Research Peptide Overview | Pure Lab

This Melanotan I Research Peptide Overview explains the historical research compound commonly associated with afamelanotide, a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone studied in melanocortin receptor biology and pigmentation pathway models. The focus here is strictly laboratory research, with attention to structure, receptor pharmacology, evidence boundaries, and the analytical documentation researchers typically review when evaluating research-use-only material.[1][2]

Fast Answer

What Melanotan I Means in Published Literature

In published scientific and regulatory literature, Melanotan I refers to a linear tridecapeptide analog of alpha-MSH with the sequence Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. DailyMed describes the corresponding pharmaceutical ingredient as a synthetic 13-amino-acid peptide, while the FDA review documents the historical aliases “Melanotan” and “Melanotan-1” for the same core molecule discussed under the name afamelanotide.[1][2]

The two defining substitutions relative to native alpha-MSH are central to why this analog appears so often in melanocortin research. Medicinal chemistry reviews describe the Met4 to Nle4 change as a way to reduce oxidation liability and the Phe7 to D-Phe7 change as a way to enhance conformational stability and resistance to proteolytic breakdown. Those changes are part of the classic structure-activity logic behind the NDP-alpha-MSH scaffold.[4][1]

Early analog-design work established why Melanotan I remained important as a research template. The original 1980 PNAS study reported markedly enhanced melanotropic potency relative to native alpha-MSH, and later FDA review material summarized the compound as more resistant to serum or proteolytic degradation and substantially more active than native alpha-MSH in bioassays. For research readers, that historical context matters because it explains why the peptide is frequently used as a reference ligand in melanocortin pathway work.[5][2]

Key identifiers researchers should confirm

• The exact linear sequence, including the Nle4 and D-Phe7 substitutions, rather than relying on a shorthand product name alone.[1][4]
• Whether the material is described under the historical name Melanotan I or the later regulated name afamelanotide when cross-checking literature and documentation.[2]
• The stated form or counterion, because pharmaceutical documentation describes afamelanotide as an acetate-containing ingredient and that detail can matter when comparing lots or reference materials.[1]

Structure and Melanocortin Pathway Context

Melanotan I sits within the broader melanocortin research field, which centers on five related receptors named MC1R through MC5R. Reviews of the receptor family describe these GPCRs as participating in distinct but overlapping biological functions, with MC1R most closely tied to pigmentation biology and with other family members involved in separate endocrine and neurobiological contexts. That family-level context is essential because a melanocortin ligand can be potent without being absolutely subtype-exclusive.[6]

Published sources generally describe Melanotan I as MC1R-focused rather than MC1R-only. DailyMed states that afamelanotide binds predominantly to MC1R, while receptor profiling work from Haskell-Luevano and colleagues reported nanomolar efficacies across multiple melanocortin receptor subtypes other than MC2R. For laboratory interpretation, that means assay design should distinguish between an MC1R-priority ligand and a perfectly selective MC1R probe, because those are not the same thing.[1][3]

In MC1R-centered models, the most commonly discussed downstream axis is Gs-mediated adenylyl cyclase activation followed by cAMP signaling. Review literature describes MC1R activation as promoting cAMP-linked programs that intersect with CREB, MITF, tyrosinase regulation, melanin synthesis, and broader UV-response biology in melanocytes. That is why Melanotan I appears repeatedly in mechanistic discussions of melanocortin signaling rather than only in simple descriptor lists of “pigment peptides.”[7][8]

Editorial note: The diagram below is an editorial synthesis of the cited literature, not a direct reproduction of a published figure.[7][8]

For researchers, the practical takeaway is that Melanotan I is usually most informative when the experimental question is clearly anchored to receptor pharmacology, signaling, or pigment-related cellular readouts. It is less useful when the label “melanocortin agonist” is treated as a substitute for subtype-specific assay design or lot-level analytical verification.[3][7][8]

What Published Studies Actually Examine

The literature around Melanotan I is strongest in three areas: analog design and potency, receptor pharmacology, and melanocyte-pathway biology. Early work established the scaffold as a potent alpha-MSH analog, receptor studies characterized its melanocortin activity profile, and cell-based studies examined morphology, tyrosinase activity, melanogenesis, and melanin composition after exposure to the peptide. That evidence base is informative, but it is also model-dependent and should be interpreted as such.[2][5][3][9][10]

Across this evidence base, the most durable mechanistic theme is MC1R-linked signaling in pigmentation-pathway models. Review literature from 2014, 2016, and 2023 consistently points back to cAMP-centered melanocortin biology, whereas broader interpretations depend much more heavily on the model system, receptor background, and assay endpoint selected by investigators. In other words, the core pathway signal is relatively strong, but the scope of interpretation still needs discipline.[7][8][11]

Another practical point for researchers is that later academic and regulatory literature often uses the name afamelanotide where older experimental literature uses Melanotan I or NDP-alpha-MSH. That naming shift does not change the underlying need for exact sequence verification, but it does mean database searches and supplier documentation review should include all major synonyms to avoid incomplete literature retrieval or mistaken compound matching.[1][2]

Analytical Testing and Documentation Priorities

For a Melanotan I research lot, identity data matter as much as purity data. Modern peptide quality evaluation is built around fitness for intended purpose, and ICH Q2(R2) frames analytical validation in terms such as identity, purity, impurity measurement, specificity or selectivity, accuracy, precision, and robustness. In peptide workflows, that usually means relying on more than one analytical method instead of treating a single number on a product page as a complete quality picture.[13][14][15]

The first checkpoint is sequence identity and expected mass. DailyMed provides the 13-residue sequence and molecular weight for afamelanotide, which gives researchers a reliable reference point when comparing a supplier’s COA against published literature. If a lot is represented only by a generic name without the exact sequence, molecular mass, and stated counterion or salt information, the documentation is incomplete for serious comparative work.[1][13][15]

The second checkpoint is chromatographic purity and related-substances review. Mant and colleagues describe reversed-phase HPLC as a central peptide analysis tool, and ICH Q2(R2) treats purity and impurity measurements as method classes that need appropriate validation and performance control. In practice, that means an HPLC trace is useful for assessing component separation, but it does not by itself prove full sequence identity or characterize all peptide-related impurities. That stronger conclusion usually requires orthogonal evidence, most commonly LC-MS or LC-HRMS.[14][13][15]

The third checkpoint is impurity characterization. FDA’s synthetic peptide guidance emphasizes that peptide-related impurities can arise from sequence differences and other modifications, and it repeatedly links impurity profiling to the need for identification, reduction, characterization, and justification. Although that document addresses regulated peptide products rather than RUO catalog materials, the analytical lesson is highly relevant for research buyers: unknown related substances are not a trivial documentation gap when the experiment depends on receptor pharmacology or pathway specificity.[16]

Batch review checklist for Melanotan I

• Exact sequence listing that matches the published NDP-alpha-MSH scaffold rather than a name-only label.[1]
• Lot-specific mass confirmation so the stated material aligns with the expected molecular identity.[15]
• Chromatographic purity data with method information, not just an isolated percentage claim.[14][13]
• Some level of related-substance or impurity description, especially if the material will be used in receptor or signaling assays.[16][15]
• Batch-specific documentation that includes a lot number, test date, and clear RUO labeling language.[13][2]

A disciplined sourcing workflow therefore looks less like “find the peptide name” and more like “verify the exact analog, confirm orthogonal identity data, inspect impurity context, and compare the documentation to the experimental endpoint.” That approach is especially useful for Melanotan I because its historical aliases, pharmaceutical naming overlap, and family resemblance to Melanotan II increase the risk of documentation shortcuts and avoidable sourcing errors.[2][12][15]

Evidence Limits and Common Confusions

Melanotan I is best understood as a well-known melanocortin research scaffold, not as a shortcut to broad claims about every topic linked to pigmentation or receptor biology. The strongest evidence base concerns peptide design, receptor engagement, and MC1R-centered signaling. That is a narrower and more scientifically stable claim set than the much broader language often seen in informal peptide discussions outside the scientific literature.[2][3][11]

Researchers should also keep receptor context in view. The melanocortin family includes five receptors with different physiological roles, and Melanotan I has been profiled as a potent agonist with activity beyond MC1R. For that reason, conclusions from one receptor system, one cell type, or one readout do not automatically transfer to another. Published evidence supports disciplined pathway interpretation, not receptor-generalized assumptions.[6][3][7]

A second common confusion is the name overlap with Melanotan II. Review literature identifies MT-I as the earlier linear NDP-alpha-MSH analog and MT-II as a later cyclic analog generated from the same broader medicinal chemistry lineage. Similar names do not make the compounds interchangeable. Sequence class, conformation, receptor behavior, and literature context all need to be checked directly.[12]

For RUO procurement, the safest scientific habit is to verify the exact molecular identity before comparing papers, assays, or suppliers. If a data sheet says only “melanotan” without sequence-level clarity, chromatographic documentation, and mass confirmation, the record is too ambiguous for serious research selection. In this category, precise nomenclature and lot-level evidence are part of compound characterization, not optional extras.[1][13][15]

FAQs

Is Melanotan I the same as afamelanotide?

In published literature, Melanotan I is the historical research name commonly associated with the synthetic alpha-MSH analog later described under the regulated name afamelanotide. The names often point to the same core sequence, but researchers should still verify the exact peptide sequence and stated form on the batch documentation rather than relying on naming conventions alone.[1][2]

What receptor does Melanotan I primarily target in published research?

Published sources generally describe Melanotan I as a melanocortin receptor agonist with predominant MC1R activity, especially in pigmentation-pathway discussions. At the same time, receptor profiling literature reports activity at other melanocortin receptor subtypes such as MC3R, MC4R, and MC5R, which is why the compound is better described as MC1R-priority rather than perfectly MC1R-exclusive.[1][3][11]

How is Melanotan I different from Melanotan II?

Melanotan I is the linear first-generation NDP-alpha-MSH analog, whereas Melanotan II is a later cyclic analog from the same broader melanocortin design history. Because that structural difference can influence conformation and pharmacology, the two compounds should not be merged under a generic “melanotan” label when reviewing literature, planning assays, or comparing supplier documentation.[12][2]

What analytical data should accompany a Melanotan I research lot?

A strong Melanotan I documentation package should include the stated sequence, molecular mass confirmation, chromatographic purity data, lot identification, and batch-specific analytical records. It is also preferable to see impurity-related information where available, because peptide identity, purity, and related substances are distinct quality questions and not interchangeable claims.[13][14][15][16]

Why are both HPLC and LC-MS relevant when evaluating Melanotan I?

HPLC and LC-MS are relevant because they answer different analytical questions. HPLC is commonly used to separate peptide components and estimate purity, while LC-MS adds orthogonal information about molecular mass and peptide-related impurities. Together, they provide a stronger evidence package for confirming that a Melanotan I lot matches its stated identity and quality profile.[14][15][13]

Next Steps

Review batch-specific documentation before selecting any research-use-only peptide. Explore Pure Lab Peptides for RUO peptide compounds with clear labeling, research-focused product information, and available documentation.

References

1. National Library of Medicine. “Label: SCENESSE – afamelanotide implant.” DailyMed. Updated 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48
2. U.S. Food and Drug Administration. “NDA/BLA Multi-disciplinary Review and Evaluation: Scenesse (afamelanotide).” FDA. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000MultidisciplineR.pdf
3. Haskell-Luevano C, Hendrata S, North C, Sawyer TK, Hadley ME, Hruby VJ, Dickinson C, Gantz I. “Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R.” Journal of Medicinal Chemistry. 1997. doi.org/10.1021/jm960840h
4. Hruby VJ. “Design of novel melanocortin receptor ligands.” European Journal of Pharmacology. 2011. doi.org/10.1016/j.ejphar.2010.10.109
5. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. “4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.” Proceedings of the National Academy of Sciences of the USA. 1980. doi.org/10.1073/pnas.77.10.5754
6. Ramachandrappa S, Gorrigan RJ, Clark AJL, Chan LF. “The melanocortin receptors and their accessory proteins.” Frontiers in Endocrinology. 2013. doi.org/10.3389/fendo.2013.00009
7. Garcia-Borron JC, Abdel-Malek Z, Jimenez-Cervantes C. “MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.” Pigment Cell & Melanoma Research. 2014. doi.org/10.1111/pcmr.12257
8. Horrell EMW, Boulanger MC, D’Orazio JA. “Melanocortin 1 Receptor: Structure, Function, and Regulation.” Frontiers in Genetics. 2016. doi.org/10.3389/fgene.2016.00095
9. Hunt G, Todd C, Cresswell JE, Thody AJ. “Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes.” Journal of Cell Science. 1994. https://pubmed.ncbi.nlm.nih.gov/8175909/
10. Hunt G, Kyne S, Wakamatsu K, Ito S, Thody AJ. “Nle4DPhe7 alpha-melanocyte-stimulating hormone increases the eumelanin:phaeomelanin ratio in cultured human melanocytes.” Journal of Investigative Dermatology. 1995. https://pubmed.ncbi.nlm.nih.gov/7798647/
11. Mun Y, Kim W, Shin D. “Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects.” International Journal of Molecular Sciences. 2023. doi.org/10.3390/ijms241512152
12. Zhou Y, Fine J, Srivastava A, et al. “Novel approaches to the design of bioavailable melanotropins.” Frontiers in Endocrinology. 2017. doi.org/10.3389/fendo.2017.00013
13. International Council for Harmonisation. “ICH Q2(R2) Guideline: Validation of Analytical Procedures.” ICH. 2023. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
14. Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. “HPLC Analysis and Purification of Peptides.” Methods in Molecular Biology. 2007. doi.org/10.1007/978-1-59745-430-8_1
15. Zeng K, Geerlof A, Vidavsky I, Gucinski A, Boyne MT II. “Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control.” The AAPS Journal. 2015. doi.org/10.1208/s12248-015-9730-z
16. U.S. Food and Drug Administration. “Guidance for Industry: Synthetic Peptides.” FDA. 2017. https://www.fda.gov/media/107622/download